Literature DB >> 10834937

TGF-beta autocrine loop regulates cell growth and myogenic differentiation in human rhabdomyosarcoma cells.

M Bouché1, R Canipari, R Melchionna, D Willems, M I Senni, M Molinaro.   

Abstract

Transforming growth factor beta (TGF) is a well-known inhibitor of myogenic differentiation as well as an autocrine product of rhabdomyosarcoma cells. We studied the role of the TGF-beta autocrine loop in regulating growth and myogenic differentiation in the human rhabdomyosarcoma cell line, RD. We previously reported that the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) induces growth arrest and myogenic differentiation in these cells, which constitutively express muscle regulatory factors. We show that TPA inhibits the activation of secreted latent TGF-beta, thus decreasing the concentration of active TGF-beta to which the cells are exposed. This event is mediated by the TPA-induced alteration of the uPA/PAI serine-protease system. Complete removal of TGF-beta, mediated by the ectopic expression of a soluble type II TGF-beta receptor dominant negative cDNA, induces growth arrest, but does not trigger differentiation. In contrast, a reduction in the TGF-beta concentration, to a range of 0.14-0.20 x 10(-2) ng/ml (which is similar to that measured in TPA-treated cells), mimics TPA-induced differentiation. Taken together, these data demonstrate that cell growth and suppression of differentiation in rhabdomyosarcoma cells require overproduction of active TGF-beta; furthermore, they show that a 'critical' concentration of TGF-beta is necessary for myogenic differentiation to occur, whereas myogenesis is abolished below and above this concentration. By impairing the TGF-beta autocrine loop, TPA stabilizes the factor concentration within the range compatible for differentiation to occur. In contrast, in human primary muscle cells a much higher concentration of exogenous TGF-beta is required for the differentiation inhibitory effect and TPA inhibits differentiation in these cells probably through a TGF-beta independent mechanism. These data thus clarify the mechanism underlying the multiple roles of TGF-beta in the regulation of both the transformed and differentiated phenotype.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10834937     DOI: 10.1096/fasebj.14.9.1147

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  16 in total

1.  Intrinsic TGF-β signaling promotes age-dependent CD8+ T cell polyfunctionality attrition.

Authors:  Rajarshi Bhadra; Magali M Moretto; Julio C Castillo; Constantinos Petrovas; Sara Ferrando-Martinez; Upasana Shokal; Manuel Leal; Richard A Koup; Ioannis Eleftherianos; Imtiaz A Khan
Journal:  J Clin Invest       Date:  2014-04-24       Impact factor: 14.808

2.  Obesity-associated extracellular mtDNA activates central TGFβ pathway to cause blood pressure increase.

Authors:  Albert Alé; Yalin Zhang; Cheng Han; Dongsheng Cai
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-11-15       Impact factor: 4.310

3.  Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation.

Authors:  Selim Kuçi; Eva Rettinger; Bernhard Voss; Gerrit Weber; Miriam Stais; Hermann Kreyenberg; Andre Willasch; Zyrafete Kuçi; Ewa Koscielniak; Stephan Klöss; Dorothee von Laer; Thomas Klingebiel; Peter Bader
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

4.  Systematic analysis of the TGF-beta/Smad signalling pathway in the rhabdomyosarcoma cell line RD.

Authors:  Hua Wang; Guang-Hua Yang; Hong Bu; Qiao Zhou; Li-Xin Guo; Shou-Li Wang; Lv Ye
Journal:  Int J Exp Pathol       Date:  2003-06       Impact factor: 1.925

5.  Terminal differentiation of Sol 8 myoblasts is retarded by a transforming growth factor-beta autocrine regulatory loop.

Authors:  Séverine Allegra; Jacques Yuan Li; José Maria Saez; Dominique Langlois
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

6.  Krüppel-like factor 6 (KLF6) promotes cell proliferation in skeletal myoblasts in response to TGFβ/Smad3 signaling.

Authors:  Mathew G Dionyssiou; Jahan Salma; Mariya Bevzyuk; Stephanie Wales; Lusine Zakharyan; John C McDermott
Journal:  Skelet Muscle       Date:  2013-04-02       Impact factor: 4.912

Review 7.  Rhabdomyosarcomas: an overview on the experimental animal models.

Authors:  Alessandra Zanola; Stefania Rossi; Fiorella Faggi; Eugenio Monti; Alessandro Fanzani
Journal:  J Cell Mol Med       Date:  2012-07       Impact factor: 5.310

8.  Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments.

Authors:  Monika Ehnman; Edoardo Missiaglia; Erika Folestad; Joanna Selfe; Carina Strell; Khin Thway; Bertha Brodin; Kristian Pietras; Janet Shipley; Arne Östman; Ulf Eriksson
Journal:  Cancer Res       Date:  2013-01-21       Impact factor: 12.701

9.  Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK).

Authors:  Nancy Dos Santos; Golareh Habibi; Michelle Wang; Jennifer H Law; Heather N Andrews; Daniel Wei; Timothy Triche; Shoukat Dedhar; Sandra E Dunn
Journal:  Transl Oncogenomics       Date:  2007-07-23

10.  Myotonic dystrophy protein kinase (DMPK) prevents ROS-induced cell death by assembling a hexokinase II-Src complex on the mitochondrial surface.

Authors:  B Pantic; E Trevisan; A Citta; M P Rigobello; O Marin; P Bernardi; S Salvatori; A Rasola
Journal:  Cell Death Dis       Date:  2013-10-17       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.